Align Technology settles patent litigation with Ormco Align Technology.

Related StoriesLife Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3 percent and 5 percentDanaher acquires Life Technology' mass spectrometry businessDanaher to obtain Beckman Coulter for $83.50 per shareAlign and Ormco also have agreed upon an exclusive collaboration over the next seven years to develop and marketplace an orthodontic item that combines the Invisalign program with Ormco’s Insignia orthodontic brackets and arch wires system to take care of the most complex instances.Toxicity end factors are defined in the protocol. Secondary end points included confirmed virologic failure or death by week 24, verified virologic failure or death through the follow-up period, and a composite of virologic failure or discontinuation of the analysis treatment through the follow-up period. Data for kids lost to follow-up had been censored for the virologic failure end point at the time of the last obtainable HIV-1 RNA measurement. Statistical Analysis The analysis included all children in cohort 2 who started the study treatment. Four children who had previously been subjected to nevirapine were incorrectly assigned to cohort 2.